DGAP-News: MOLOGEN AG: Successful completion of capital increase with substantial oversubscription

Press release N 7 / 2019 of 2 April 2019

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

MOLOGEN AG: Successful completion of capital increase with substantial oversubscription

- Placement of around 2 million new shares - Order book considerably oversubscribed

- Gross proceeds of around EUR4.2 million

Berlin, 2 April 2019 - The biopharmaceutical company MOLOGEN AG has successfully completed its capital increase from authorized capital. In total 2,012,220 new shares were issued to investors at a subscription price of EUR2.10, raising the share capital of the Company to EUR12,073,322. Once entered in the Commercial Register, all new shares will be fully entitled to dividend payments as of 1 January 2018 and are scheduled to be included in the existing listing on the regulated market of the Frankfurt stock exchange (Prime Standard) presumably on 11 April 2019. The gross proceeds amounting to around EUR4.2 million are expected to be used for the financing of MOLOGEN's business operations until the end of 2019 and especially for the financing of the ongoing pivotal phase III study IMPALA.

"We are delighted about the success of the capital increase and would like to thank those investors who, despite the various challenges the company is currently facing, have placed their trust in us. This cash inflow will in particular secure the financing of our pivotal IMPALA trial until read-out of the primary endpoint," says Dr Matthias Baumann, Chief Medical Officer (CMO) of MOLOGEN AG.

The transaction was executed by KAS Bank N.V., Frankfurt.
Gross proceeds of around EUR4.2 million - primarily for the financing of the ongoing pivotal phase III study IMPALA
As part of the capital increase, MOLOGEN placed a total of 2,012,220 shares and generated gross proceeds of around EUR4.2 million. The new shares were offered to existing shareholders for subscription during the subscription period which lasted from 19 March 2019 to (and including) 1 April 2019 at a price of EUR2.10 each. The subscription ratio was 1:5 (i.e. one new share per 5 existing shares of the Company).

The gross proceeds of around EUR4.2 million will be used for the financing of MOLOGEN's business operations beyond July 2019 and especially for the financing of the ongoing pivotal phase III study IMPALA with lefitolimod in the indication of colorectal cancer. These funds are expected to finance the Company until the end of 2019.

Inclusion of the new shares under the Company's existing listing (ISIN DE000A2LQ900, SIN A2L Q90) is planned for 11 April 2019.

Important note:
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this press release have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from registration or in a transaction not subject to the registration requirements of the Securities Act. There will be no public offer of the securities in the United States of America. Subject to certain exceptions under the Securities Act, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published.
In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 37
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.